Thermo Fisher Scientific Expands Millersburg, Pa. Bioprocessing Manufacturing Site
$40 million expansion will support increased production of single-use technology for critical vaccines and biologics
Thermo Fisher Scientific is investing $40 million to expand its single-use technology (SUT) manufacturing facility in Millersburg, Pa. The expansion is part of the company’s $650 million multi-year investment, announced last year, to help ensure flexible, scalable and reliable bioprocessing production capacity exists for critical materials used in developing new and existing biologics and vaccines, including for COVID-19.
Single-use technologies enable development of a growing number of biological drugs and vaccines, creating unprecedented demand for these products. The Millersburg site expansion will add significant capacity to continue providing the biopharma industry with the technology and materials needed to assist in developing new vaccines, cancer treatments and breakthrough therapies for other conditions.
“Since the start of the pandemic, the Millersburg site has been instrumental in supporting more than 20 pharmaceutical partners developing lifesaving therapies and vaccines,” said Mitch Kennedy, president, single use technologies, Thermo Fisher Scientific. “During the pandemic, our colleagues in Millersburg and around the world answered the call for increased production. Our expanded bioprocessing capabilities will ensure that we can continue to deliver essential supplies to our customers as demand surges.”
Thermo Fisher acquired the Millersburg facility in 2015, and over the last two years has expanded and modernised the warehouse and clean rooms. The second phase of the site expansion includes a new, 47,000-square-foot warehouse and creation of 100 new jobs at various levels. Once fully renovated by mid 2023, Thermo Fisher anticipates that the site will employ more than 1,000 people.
“Pennsylvania is proud that Thermo Fisher Scientific is expanding in Dauphin County and is creating 100 new jobs in the region,” said Governor Tom Wolf. “Pennsylvania is a key destination for groundbreaking businesses with our highly educated, skilled, and talented workforce, leading universities, and location near other major cities. The bioprocessing solutions that Thermo Fisher Scientific will produce in Millersburg will help to power the local economy and strengthen our position in the science and technology sectors.”
“We are tremendously grateful for the vision, investment and job creation Thermo Fisher Scientific is bringing to Millersburg and our hardworking local families,” said U.S. Representative, Scott Perry. “We know our folks will continue to make this world-class company and our community proud.”
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance